Published in Clin Exp Immunol on January 01, 2006
The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol (2009) 1.88
Immunomodulatory dietary polysaccharides: a systematic review of the literature. Nutr J (2010) 1.20
Oral and systemic administration of beta-glucan protects against lipopolysaccharide-induced shock and organ injury in rats. Clin Exp Immunol (2007) 0.87
Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses. J Immune Based Ther Vaccines (2006) 0.86
Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan. Nutr J (2014) 0.83
Hochuekkito, a Kampo (Traditional Japanese Herbal) Medicine, and its Polysaccharide Portion Stimulate G-CSF Secretion from Intestinal Epithelial Cells. Evid Based Complement Alternat Med (2008) 0.82
Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(α)anthracene and decreases cell proliferation: comparison with tamoxifen. J Cancer Res Clin Oncol (2012) 0.82
Oral administration of beta-1,3/1,6-glucan to dogs temporally changes total and antigen-specific IgA and IgM. Clin Vaccine Immunol (2009) 0.81
β-Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers. Food Sci Nutr (2014) 0.79
Improvement in Human Immune Function with Changes in Intestinal Microbiota by Salacia reticulata Extract Ingestion: A Randomized Placebo-Controlled Trial. PLoS One (2015) 0.77
Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med (2003) 7.38
Dectin-1 mediates the biological effects of beta-glucans. J Exp Med (2003) 5.82
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood (2004) 2.84
Modulating Toll-like receptor mediated signaling by (1-->3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res (2004) 1.69
Overview of (1-->3)-beta-D-glucan immunobiology. Mediators Inflamm (1997) 1.55
Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol Immunol (2004) 1.41
A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg (1994) 1.31
Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother (2002) 1.22
Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynecol Obstet (1993) 1.11
Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan. Infect Immun (1999) 1.10
PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology (1999) 1.10
Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J Pediatr Surg (2001) 1.10
Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. J Oral Pathol Med (2003) 1.07
Effect of macrophage stimulation on collagen biosynthesis in the healing wound. Am Surg (1997) 1.03
Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol (1998) 1.00
Effect of glucan on granulopoiesis and macrophage genesis in mice. Cancer Res (1977) 0.98
Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection. Antimicrob Agents Chemother (1998) 0.97
Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch Surg (1999) 0.95
Glucan: mechanisms involved in its "radioprotective" effect. J Leukoc Biol (1987) 0.93
The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. Acta Haematol (1999) 0.91
Glucan as stimulator of hematopoiesis in normal and gamma-irradiated mice. A survey of the authors' results. Int J Immunopharmacol (1998) 0.86
Inhibition of adherence of Candida albicans and Candida dubliniensis to a resin composite restorative dental material by salivary secretory IgA and monoclonal antibodies. Oral Dis (2004) 0.84
Recurrent parotitis in selective IgA deficiency. Pediatr Allergy Immunol (2004) 0.84
Activation of AP-1 and SP1 correlates with wound growth factor gene expression in glucan-treated human fibroblasts. Int Immunopharmacol (2002) 0.83
Soluble polyglycans enhance recovery from cobalt-60--induced hemopoietic injury. J Biol Response Mod (1984) 0.83
Maturation of dendritic cells induced by Candida beta-D-glucan. Int Immunopharmacol (2002) 0.81
Effect of glucan, a macrophage activator, on murine hemopoietic cell proliferation in diffusion chambers in mice. Cancer Res (1978) 0.78
Glucan enhances survival in an intraabdominal infection model. J Surg Res (1989) 0.78
Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. J Gen Microbiol (1986) 5.05
Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis (1989) 3.66
Natural competence in the genus Streptococcus: evidence that streptococci can change pherotype by interspecies recombinational exchanges. J Bacteriol (1997) 2.86
Identification of the streptococcal competence-pheromone receptor. Mol Microbiol (1996) 2.85
V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood (2001) 2.50
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect (2011) 2.38
Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J Exp Med (1999) 2.24
Identification of DNA binding sites for ComE, a key regulator of natural competence in Streptococcus pneumoniae. Mol Microbiol (1999) 2.18
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
[Clinical manifestations caused by group A streptococci]. Tidsskr Nor Laegeforen (1990) 1.95
An outbreak of group B meningococcal disease: tracing the causative strain of Neisseria meningitidis by DNA fingerprinting. J Clin Microbiol (1986) 1.88
Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982. NIPH Ann (1983) 1.73
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
Elution and characterization of lymphocytes from rheumatoid inflammatory tissue. Scand J Immunol (1975) 1.60
Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol (1998) 1.55
Direct detection of Mycobacterium tuberculosis complex in clinical samples from patients in Norway by ligase chain reaction. J Clin Microbiol (1997) 1.54
Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease in Norway, Winter 1981-1982. NIPH Ann (1983) 1.54
Primary immunodeficiency diseases in Norway. J Clin Immunol (2000) 1.48
Factors preceding the onset of meningococcal disease, with special emphasis on passive smoking, symptoms of ill health. NIPH Ann (1983) 1.44
Persistent strains of coagulase-negative staphylococci in a neonatal intensive care unit: virulence factors and invasiveness. Clin Microbiol Infect (2007) 1.43
[Diagnosis and treatment of infections in a neonatal unit--viral infections, spirochete infections and toxoplasma infections]. Tidsskr Nor Laegeforen (1993) 1.39
Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med (2001) 1.36
Systemic meningococcal disease: a model infection to study acute endotoxinemia in man. Prog Clin Biol Res (1988) 1.30
Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges. Antimicrob Agents Chemother (1986) 1.27
Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun (1999) 1.18
Case fatality of meningococcal disease in western Norway. Scand J Infect Dis (1987) 1.17
Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect (2001) 1.09
Streptococcus phocae sp. nov., a new species isolated from clinical specimens from seals. Int J Syst Bacteriol (1994) 1.08
Rheumatoid factor plaque-forming cells in rheumatoid synovial tissue. Clin Exp Immunol (1977) 1.05
Genetic transformation in Streptococcus sanguis. Distribution of competence and competence factors in a collection of strains. Acta Pathol Microbiol Scand B (1979) 1.03
Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine (1997) 1.02
Rapid flow cytometric assessment of mecillinam and ampicillin bacterial susceptibility. J Antimicrob Chemother (1996) 1.02
The early phase of meningococcal disease. NIPH Ann (1983) 1.02
Human faecal immunoglobulins in healthy infants and children, and in some with diseases affecting the intestinal tract or the immune system. Clin Exp Immunol (1975) 1.02
Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine (1999) 1.01
Phagocytosis of bacteria by human leukocytes measured by flow cytometry. Proc Soc Exp Biol Med (1983) 1.00
Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol (1995) 1.00
Occurrence of moulds in drinking water. J Appl Microbiol (2007) 1.00
Identification and analysis of the gap region in the 23S ribosomal RNA from Actinobacillus actinomycetemcomitans. J Dent Res (1992) 1.00
CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today (1996) 1.00
Membrane characteristics of adherent cells dissociated from rheumatoid synovial tissue. Clin Exp Immunol (1977) 0.97
Genetic transformation in Streptococcus sanguis. Effects on genetic transformation by culture filtrates of Streptococcus sanguis (serogroups H and W) and streptococcus mitis (mitior) with reference to identification. Acta Pathol Microbiol Immunol Scand B (1985) 0.96
A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin. Vaccine (1997) 0.96
Virulence markers in patient and carrier strains of Neisseria meningitidis. Scand J Infect Dis (1984) 0.96
Genetic transformation in Streptococcus sanguis. Competence factor and competence factor inactivator. Acta Pathol Microbiol Scand B (1981) 0.96
In vitro mitogen stimulation of synovial fluid lymphocytes from rheumatoid arthritis and juvenile rheumatoid arthritis patients: dissociation between the response to antigens and polyclonal mitogens. Scand J Immunol (1978) 0.96
Granulocyte-macrophage colony-stimulating factor, but not macrophage colony-stimulating factor, suppresses basal and lipopolysaccharide-stimulated complement factor production in human monocytes. J Immunol (1993) 0.95
Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infect Immun (1996) 0.95
Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J Immunol Methods (2000) 0.94
Psychological outcome in children treated for brain tumor. Pediatr Hematol Oncol (1999) 0.93
Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis (1992) 0.93
Endotoxin liberation from Neisseria meningitidis isolated from carriers and clinical cases. Scand J Infect Dis (1987) 0.92
Immunoglobulins and other serum proteins in feces from infants and children. Scand J Immunol (1973) 0.92
Immunoglobulins in feces from infants fed human or bovine milk. Scand J Immunol (1974) 0.92
Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine (2000) 0.91
The latency of serum acute phase proteins in meningococcal septicemia, with special emphasis on lactoferrin. Clin Chim Acta (1984) 0.91
Rapid assessment of ceftazidime, ciprofloxacin, and gentamicin susceptibility in exponentially-growing E. coli cells by means of flow cytometry. Cytometry (1997) 0.91
Effect of tetracyclines and UV light on oxygen consumption by human leukocytes. Antimicrob Agents Chemother (1984) 0.91
Antigen and unspecific mitogen stimulation of lymphocytes eluted from rheumatoid inflammatory tissue. Scand J Immunol (1976) 0.89
Cervical secretions in pregnant women colonized rectally with group B streptococci have high levels of antibodies to serotype III polysaccharide capsular antigen and protein R. Scand J Immunol (1998) 0.88
Blood culture isolates during 6 years in a tertiary neonatal intensive care unit. Scand J Infect Dis (1998) 0.88
Low thymic output in the 22q11.2 deletion syndrome measured by CCR9+CD45RA+ T cell counts and T cell receptor rearrangement excision circles. Clin Exp Immunol (2010) 0.88
Human opsonins to meningococci after vaccination. Infect Immun (1984) 0.88
A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J Med Microbiol (2000) 0.88
An evaluation of two immunological methods in the diagnosis of bacterial meningitis: the effect of ultrasonic treatment of the cerebrospinal fluid. Scand J Infect Dis (1977) 0.87
Genetic transformation in Streptococcus sanguis. Spontaneous and induced competence of selected strains. Acta Pathol Microbiol Scand B (1979) 0.87
Simultaneous measurement of phagocytosis and phagosomal pH by flow cytometry: role of polymorphonuclear neutrophilic leukocyte granules in phagosome acidification. Cytometry (1983) 0.87
Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis (1998) 0.86
Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun (1999) 0.86
Clinical assessment of gestational age in the newborn infant. An evaluation of two methods. Acta Paediatr Scand (1981) 0.86
Human fetal agglutinins to rabbit erythrocytes. Scand J Immunol (1974) 0.86
New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand J Immunol (2008) 0.86
Standardization of a chemiluminescence method for the measurement of meningococcal opsonins using ethanol fixed meningococci. Acta Pathol Microbiol Immunol Scand C (1987) 0.85
Juvenile GM 1 gangliosidosis: clinical, pathological, chemical and enzymatic studies. Clin Genet (1972) 0.85
Factors important for the measurement of chemiluminescence production by polymorphonuclear leukocytes. J Immunol Methods (1986) 0.85
Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia. Clin Exp Immunol (2005) 0.85
Diagnosis of Haemophilus influenzae type b pericarditis by counterimmunoelectrophoresis. Scand J Infect Dis (1978) 0.84
How reliable and useful is the latex agglutination test in diagnosing streptococcal throat infection in general practice? Scand J Prim Health Care (1987) 0.84
Colonization by Candida in children with cancer, children with cystic fibrosis, and healthy controls. Clin Microbiol Infect (2011) 0.83
Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine (2000) 0.83
Clinical management of prepubertal periodontitis in 2 siblings with Papillon-Lefèvre syndrome. J Clin Periodontol (1987) 0.83
Human milk immunoglobulins and agglutinins to rabbit erythrocytes. Int Arch Allergy Appl Immunol (1974) 0.83
Fragments of immunoglobulins in human faeces. Acta Pathol Microbiol Scand C (1976) 0.83
Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect Immun (2001) 0.83
Immunoglobulin E in feces from children with allergy. Evidence of local production of IgE in the gut. Int Arch Allergy Appl Immunol (1985) 0.83
Effects of bromocriptine on hormone production and cell growth in cultured rat pituitary cells. Acta Endocrinol (Copenh) (1985) 0.83
Relationship of serotype, leukotoxin gene type and lysogeny in Actinobacillus actinomycetemcomitans to periodontal disease status. Eur J Oral Sci (1997) 0.82
Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol (2007) 0.82
Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand J Immunol (2006) 0.82
In vitro release of lysozyme from monocytes and granulocytes. J Leukoc Biol (1984) 0.82
Discrepancy between results of a commercial enzyme immunoassay kit and immunofluorescence staining for detection of respiratory syncytial virus antigen. Eur J Clin Microbiol Infect Dis (1998) 0.82
Cell-specific expression and function of adenylyl cyclases in rat pituitary tumour cell lines. Eur J Biochem (1994) 0.82
Antigens Common to Scabies and House dust Mites. Allergy (1981) 0.81
Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-cell-tumor-bearing rats, and the influence of bromocriptine treatment. Life Sci (1986) 0.81
Acute response of parathyroid hormone in congenital osteopetrosis. Acta Paediatr Scand Suppl (1979) 0.81
The impact of an early truncating founder ATM mutation on immunoglobulins, specific antibodies and lymphocyte populations in ataxia-telangiectasia patients and their parents. Clin Exp Immunol (2004) 0.81